Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study

Jay Herson, Wataru W. Sutow, Karin Elder, Teresa J. Vietti, John M. Falletta, William M. Crist, Tribhawan S. Vats, Thomas Miale

Research output: Contribution to journalArticlepeer-review


This report updates experience with the CONPADRI‐I, COMPADRI‐II, and COMPADRI‐III adjuvant chemotherapy programs for the treatment of nonmetastatic osteosarcoma. A total of 200 patients received one of the three regimens. The analysis of response to treatment is based on disease‐free survival time (DFS time). The effect of treatment, age, sex, site of disease involvement, and race on DFS time were investigated. Cox's life‐table regression analysis found only sex to have a significant effect on DFS time with males having 1.8 times the risk of recurrence or death per unit time as female patients (P = 0.004). An analysis of the 81 patients still alive and disease‐free 18 months after the start of treatment shows significantly longer DFS time for CONPADRI‐I than COMPADRI‐II patients (P = 0.01). This trend is true for both male (P = 0.12) and female (P = 0.08) patients.

Original languageEnglish (US)
Pages (from-to)343-352
Number of pages10
JournalMedical and Pediatric Oncology
Issue number4
StatePublished - 1980
Externally publishedYes


  • adjuvant therapy
  • chemotherapy
  • osteosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study'. Together they form a unique fingerprint.

Cite this